At a glance
ClinicalIndex Comparison Record- ✓Stage IIIB or IV NSCLC with documented disease progression or recurrence after platinum-based chemotherapy plus ≥1 additional regimen
- ✓PD-L1 positive tumor (≥25% membrane staining for Cohorts 1–2, or ≥90% for Cohort 3)
- ✓Age ≥18 years
- ✓WHO Performance Status 0 or 1
- ✕Prior exposure to anti-PD-1 or anti-PD-L1 antibodies
- ✕Brain metastases or spinal cord compression unless asymptomatic, treated, and stable (not requiring steroids)
- ✕Active or prior autoimmune disease or immunodeficiency history
- ✕Severe or uncontrolled systemic disease, including active bleeding, hepatitis B/C/HIV, or active infections
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen
In Brief
A Phase 2 clinical trial evaluating MEDI4736 for Non-Small Cell Lung Cancer. Completed, enrolled 446 participants across 139 sites in 18 countries.
Detailed Summary
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability
Study Details
Timeline
Interventions
MEDI4736 (durvalumab) by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Patients who achieve CR, PR or SD through the end of the initial 12-month treatment period can restart treatment with MEDI4736 (durvalumab) when they eventually do progress. This retreatment period can continue for as long as the investigator considers to patient to be receiving clinical benefit.